<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030589</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069179</org_study_id>
    <secondary_id>MILL-61896</secondary_id>
    <secondary_id>LIGAND-MILL-61896</secondary_id>
    <secondary_id>NU-IRB-837-002</secondary_id>
    <nct_id>NCT00030589</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells&#xD;
      more sensitive to light to kill cancer cells. Photosensitizing drugs, such as methoxsalen,&#xD;
      are absorbed by cancer cells and, when exposed to light, become active and kill the cancer&#xD;
      cells. Combining chemotherapy with photodynamic therapy may be an effective treatment for&#xD;
      cutaneous T-cell lymphoma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of combining different doses of&#xD;
      bexarotene with photodynamic therapy in treating patients who have stage IB or stage IIA&#xD;
      cutaneous T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of 2 different doses of bexarotene administered with ultraviolet A&#xD;
           light therapy with methoxsalen (PUVA) in patients with stage IB or IIA cutaneous T-cell&#xD;
           lymphoma.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to one&#xD;
      of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a lower dose of oral bexarotene once daily on weeks 1-26.&#xD;
           Patients also receive ultraviolet A light therapy with oral methoxsalen 3 times weekly&#xD;
           on weeks 2-26.&#xD;
&#xD;
        -  Arm II: Patients receive a higher dose of oral bexarotene once daily on weeks 1-26.&#xD;
           Patients also receive ultraviolet A light therapy as in arm I.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxsalen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UV light therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cutaneous T-cell lymphoma within the past year&#xD;
&#xD;
          -  Stage IB or IIA disease&#xD;
&#xD;
               -  No prior diagnosis more advanced than stage IIA disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Absolute lymphocyte count normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  No significant hepatic dysfunction&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
          -  Calcium no greater than 11.5 mg/dL&#xD;
&#xD;
          -  No significant renal dysfunction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 1 month&#xD;
             after study participation&#xD;
&#xD;
          -  Fasting triglycerides normal (fenofibrate or another anti-lipemic agent allowed except&#xD;
             gemfibrozil)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other concurrent known serious medical illness or infection that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No prior uncontrolled hyperlipidemia&#xD;
&#xD;
          -  No pancreatitis or clinically significant risk factors for developing pancreatitis&#xD;
&#xD;
          -  No known allergy or sensitivity to retinoid class drugs or fenofibrate or&#xD;
             idiosyncratic reactions to psoralen compounds&#xD;
&#xD;
          -  No history of light-sensitive disease states (e.g., lupus, porphyria, or albinism) or&#xD;
             aphakia&#xD;
&#xD;
          -  No prior or concurrent melanoma or invasive squamous cell carcinoma&#xD;
&#xD;
          -  No pre-existing gallbladder disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior systemic anticancer interferon&#xD;
&#xD;
          -  No prior systemic anticancer denileukin diftitox&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 30 days since prior topical anticancer carmustine or mechlorethamine&#xD;
&#xD;
          -  No prior systemic anticancer alkaloid chemotherapy&#xD;
&#xD;
          -  No other concurrent systemic or topical anticancer chemotherapy (e.g., methotrexate or&#xD;
             cyclophosphamide)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 30 days since prior topical anticancer corticosteroids&#xD;
&#xD;
          -  No concurrent systemic or topical anticancer corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent localized radiotherapy to specific study lesions except at&#xD;
             investigator's discretion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior systemic anticancer therapy&#xD;
&#xD;
          -  At least 30 days since prior topical anticancer therapy (e.g., ultraviolet B light or&#xD;
             psoralen-ultraviolet-light therapy)&#xD;
&#xD;
          -  At least 30 days since prior participation in another investigational drug study&#xD;
&#xD;
          -  At least 30 days since prior vitamin A (at doses of more than 15,000 IU/day) or other&#xD;
             retinoid class drugs&#xD;
&#xD;
          -  No other concurrent systemic or topical anticancer drugs or therapies&#xD;
&#xD;
          -  No other concurrent systemic retinoid class drugs, beta-carotene compounds, or vitamin&#xD;
             A (at doses of more than 15,000 IU/day)&#xD;
&#xD;
          -  No other concurrent investigational medication&#xD;
&#xD;
          -  No concurrent gemfibrozil&#xD;
&#xD;
          -  No concurrent statin class anti-lipemics combined with fibrate class anti-lipemics&#xD;
             (e.g., atorvastatin with fenofibrate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Guitart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Science Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010-0510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian-St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70459-0059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118-2393</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StonyBrook Dermatology Associates, P.C.</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital Center - Roosevelt Division</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knoxville Dermatology Group, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
    <mesh_term>Methoxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

